Prof. GP Talwar is Director Research at the Talwar Research Foundation, a Scientific and Industrial Research Organization (SIRO) recognized by DSIR, Govt of India. He was Professor & Head Biochemistry, All India Institute of Medical Sciences New Delhi 1965-83, Jawaharlal Nehru Fellow 1979-81, Scholar-in Residence National Institutes of Health Bethesda 1982-86, and Founder Director, National Institute of Immunology 1983-94, besides Wellcome Professor Johns Hopkins Baltimore 1995 and Professor of Eminence International Centre of Genetic Engineering & Biotechnology 1994-99.
Amongst many he received the National Award in Bio-Medicine, Basanti Devi Amirchand Prize of ICMR, National Lecturer UGC, JC Bose Award Life Sciences, FICCI Award, Sunderlal Hora and Golden Jubilee Commemoration Medals of Indian National Science Academy, Jalma Trust Prize in Leprosy, Rameshwardas Birla National Award, Glaxo oration, National Academy of Medical Sciences, Ranbaxy Research Award, Mastrionni-Segal Award, Friedrich von Siemens Lecture. Life Time Achievement Award of AIIMS for Outstanding Contributions in Medical Sciences and Humanity.
He has been the President of the Indian Immunology Society, Endocrine Society of India, Indian College of Allergy & Applied Immunology, Association of Clinical Biochemists of India & Indian Academy of Vaccinology. He was elected as the President of the International Society of Immunology of Reproduction and was the first President of the Federation of Immunological Societies of Asia-Oceana.
Prof. Talwar was conferred Padma Bhushan by President of India & Officier de la Legion d’Honneur by President of France.
He has published over 600 publications in reputed Journals. He is editor & author of 10 books & Monographs. Besides basic research, his notable research contributions are:
· Mycobacterium indicus pranii: A unique vaccine based on a non-pathogenic organism usable for treatment of Leprosy. It is a potent invigorator of immune responses and has multiple additional applications for treatment of Category II Difficult to treat tuberculosis, ano-genital warts, etc. The vaccine is approved by the DCGI India and USFDA. M/s Cadila Pharma markets the vaccine.
· Development of Polyherbal Microbicide BASANT and Probiotics Pro-vag-health for Reproductive Health of Women